ClinicalTrials.gg
RecruitingNCT06299332Updated Mar 7, 2024

Safety and Efficacy of Bi-Polar Radiofrequency for the Treatment of Erectile Dysfunction

An interventional study of Device treatment in Erectile Dysfunction, sponsored by InMode MD Ltd.. Recruiting at 2 sites in United States. Open to male participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-07.

Sponsored by InMode MD Ltd. (part of InMode Ltd.) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Jun 2023, registered Nov 2023).
  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 180 studies in Erectile Dysfunction with a site in United States — 26 open to participants now, 31 under way, 3 of them phase 3. Erectile Dysfunction · United States.

Planned enrollment
121st of 164
20 · median 75
Started
2023
with 11 others
No phase
62 of 180
16 open now
Primary completion
2024-05
later than 1 of 30 live
Registered
160th of 180
by date

Among the 180 studies in Erectile Dysfunction with a site in United States, this one is the 121st largest by planned enrollment of the 164 interventional ones that give a count, is one of 12 that started in 2023, is one of 62 with no phase, reaches primary completion later than 1 of the 30 other live ones, and was the 160th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

26 of the 180 studies in Erectile Dysfunction with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 40 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies in Erectile Dysfunction with a site in United States, or all of them as a file.
02

Study summary

The goal of this prospective pilot study is to learn about the Safety and Efficacy of Radiofrequency (RF) for the Treatment of Erectile Dysfunction. This research study is trying to determine if RF therapy is safe and effective in patients with symptoms of erectile dysfunction (ED).

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult male between ≥40 and ≤80 years of age
  2. Subjects with a history of self-reported erectile dysfunction lasting for over 6 months and not more than 5 years.
  3. The subject is PDE5i responsive, meaning he is able to achieve and maintain an erection under the effect of the maximal dosage of PDE5i
  4. The subject has been in a stable heterosexual relationship for over 3 months prior to enrollment.
  5. A minimum of 4 sexual attempts during the last two weeks prior to enrollment.
  6. Abstinence from taking PDE5 for two weeks (washout) after enrolment and 2 weeks before each follow up visit/call.
  7. IIEF-EF score between 11 and 25.
  8. Testosterone level 300-1000 mg/dL within 1 month prior to the enrollment/baseline.
  9. level ≤ 8.5% within 1 month prior to enrollemnt/baseline.
  10. Subject has at EHS score ≥ 1 (natural tumescence during sexual stimulation).
  11. The subjects should understand the information provided about the investigative nature of the treatment, possible benefits and side effects, and are willing to sign the Form
  12. If the FirmTech Ring is provided, the participants must be willing to use the ring according to the instructions.
  13. The subjects should be willing to comply with the study procedure and schedule, including follow up visits.
  14. Agreement/ability to abstain from erectile dysfunction medications or any device treatments for the duration of the study, i.e., the time between the treatment visit and the final study visit.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of co-existing Neurological disease or other systemic disease conditions such as Alzheimer or Parkinson disease which affects erectile function (at the discretion of the investigator)
  2. History of radical prostatectomy or extensive pelvic surgery ever
  3. Psychiatric diagnosis or medications such as antidepressants which affects erectile function or any other medications at the discretion of the investigator.
  4. Anatomical malformation of the penis, including Peyronie's disease.
  5. Testosterone level \<300 or >1000 ng/dL within 1 month prior to enrollment.
  6. Diabetes type I
  7. Diabetes Type II with level > 8.5% within 1 month prior to enrollment.
  8. Unwillingness to abstain from systemic medications known to cause ED for the study duration.
  9. Internal defibrillator, pacemaker or any other implanted electrical device anywhere in the body
  10. Permanent metal implant in the treatment area
  11. Any surgery in the treatment area in the last 3 months
  12. Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles in the facial area
  13. Impaired immune system due to diseases such as AIDS and , or use of immunosuppressive medications
  14. Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.
  15. Poorly controlled endocrine disorders, such as diabetes, thyroid dysfunction
  16. Any active condition in the treatment area, such as but not limited to open sores, psoriasis, eczema, vitiligo, herpes and rash.
  17. History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin
  18. Severe concurrent conditions, such as cardiac disorders, sensory disturbances.
  19. Use of Isotretinoin (Accutane®) within 30 days prior to treatment.
  20. Participation in another study within 30 days prior to screening.

    -

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Device Treatment

    Eligible subjects will receive 6 weekly treatments with the Forma Applicator according to the study protocol and will return for two follow up visits 1- and 3-months post treatment. Two further telephone feedback checks will be carried out 6 months and 12 months following the last treatment visit.

    Device: Device treatment

Interventions

  • DeviceDevice treatment

    20 heterosexual males clinically diagnosed with Erectile Dysfunction will receive 6 weekly treatments with the Forma Applicator according to the study protocol and will return for two follow up visits 1- and 3-months post treatment. Two further telephone feedback checks will be carried out 6 months and 12 months following the last treatment visit

06

What researchers measure

Primary outcomes

  1. Change in ED symptoms, following the RF treatment

    Change in ED symptoms, following the RF treatment measured by THE INTERNATIONAL INDEX OF ERECTILE FUNCTION - ERECTILE FUNCTION (IIEF-EF) questionnaire score. The IIEF-5 score is the sum of the ordinal responses to the 5 items.(1 to 5 ) 22-25: No erectile dysfunction 17-21: Mild erectile dysfunction 12-16: Mild to moderate erectile dysfunction 8-11: Moderate erectile dysfunction 5-7: Severe erectile dysfunction

    Time frame: 3 months

Secondary outcomes

  1. Change in sexual activity leading to optimal penetration

    Change in sexual activity leading to optimal penetration measured by SEP- Sexual Encounter Profile questionnaire. The SEP questionnaire consists of 5 items addressing the sexual events and subject experiences when attempting intercourse. Efficacy of RF treatment evaluated using the change in percentage of "yes" responses to Sexual Encounter Profile (SEP) Questions 2 and 3

    Time frame: 3 months

  2. Evaluate efficacy of the RF treatment for erectile function

    Proportion of subject responses to Global Assessment Questionnaire (GAQ) consisting of 2 questions (Yes or No): Question 1 'Has the treatment you have been taking improved your erectile function?' and if necessary, Question 2 'If yes, has the treatment improved your ability to engage in sexual activity?'.

    Time frame: 3 months

  3. Evaluate efficacy of the RF treatment for erectile function

    Proportion of subject responses to Global Assessment Questionnaire (GAQ) consisting of 2 questions (Yes or No): Question 1 'Has the treatment you have been taking improved your erectile function?' and if necessary, Question 2 'If yes, has the treatment improved your ability to engage in sexual activity?'.

    Time frame: 6 months

  4. Evaluate efficacy of the RF treatment for erectile function

    Proportion of subject responses to Global Assessment Questionnaire (GAQ) consisting of 2 questions (Yes or No): Question 1 'Has the treatment you have been taking improved your erectile function?' and if necessary, Question 2 'If yes, has the treatment improved your ability to engage in sexual activity?'.

    Time frame: 12 months

  5. Evaluate efficacy of the RF treatment for hardness of erection

    To assess the effectiveness of RF treatment for erectile dysfunction with the Erectile Hardness Score (EHS) questionnaire The Erection Hardness Score is a self-reported tool that measures the hardness of an erection. It involves a scale report from 0 to 4, 4 being the best quality of erection.

    Time frame: 3 months

Other outcomes

  1. Measuring pain level during the procedure

    NPRS is a unidimensional measure of pain intensity in adults. The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable").

    Time frame: During the procedure

07

Study locations

2 of 2 sites recruiting
  • LC Medical 140 W 58th St, Suite A New York, NY 10019
    New York, New York 10019, United States
    Recruiting
    • Lanna Cheuck · Contact929-492-2052
  • Washington Heights Urology
    New York, New York 10032, United States
    Recruiting
    • Robert Valenzuela · Contact212-781-9696
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for May 2024, 11 months after the start.

Of 137 interventional studies with no phase under Erectile Dysfunction, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 52. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Mar 7, 2024
StartActual
Jun 23, 2023
Primary completionEst.
May 2024
CompletionEst.
May 2025
Last update
Mar 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06299332
Lead sponsor
InMode MD Ltd.
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Jun 23, 2023
Primary completion
May 2024 (estimated)
Completion
May 2025 (estimated)
Last update
Mar 7, 2024

Study contacts

MEITAL MATALON
Contact
meital.matalon@inmodemd.com
9492396522
Maria Shusterman
Contact
maria.shusterman@inmodemd.com
9492396522
Robert Valenzuela, MD
principal investigator
Lanna Cheuck, MD
principal investigator

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion